Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The School of Human Development (SHD) is a longevity-focused healthcare and biotechnology company that specializes in the science of aging and health optimization. Founded by Dr. Sandra Kaufmann, the company translates complex molecular biology into actionable protocols designed to slow the cellular aging process and extend human healthspan. SHD provides evidence-based guidance on pharmacological agents, nutraceuticals, and lifestyle interventions that target the primary hallmarks of aging, such as DNA damage and mitochondrial decay. Their services include personalized longevity consulting and educational resources based on the Kaufmann Protocol, a systematic approach to cellular maintenance. By bridging the gap between clinical research and consumer health, the company aims to provide a comprehensive framework for long-term biological preservation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on School of Human Development.